Atossa Therapeutics, Inc.
ATOSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Atossa Therapeutics, Inc. focuses on Biotechnology services and products. Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Valued at $25.1M, ATOS is a micro-cap name in its sector. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.
Market Cap
$25.1M
Beta
1.27
P/E (TTM)
—
P/E (Fwd)
-0.57
EPS (TTM)
$-4.37
EPS (Fwd)
$-4.38
ROE
-89.2%
ROA
-50.7%
Cash
$26.1M
Total Debt
$0
Free CF
-$23.3M
52W Change
-79.3%
Annual Financials
Cash vs Debt
Where ATOS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ATOS finished 39.11% below its 150-day moving average ($4.04) and 56.69% below its 200-day moving average ($5.68). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ATOS overbought or oversold?
At the September 3, 2026 close, ATOS's RSI(14) was 45.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Atossa Therapeutics, Inc. reports $26.1M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$23.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -89.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Atossa Therapeutics, Inc. and its sector.